Organon & Co. (USD) Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

Organon & Co. (USD) Active

30 Hudson Street, Jersey City, NJ, US, 07302

Stock Price USD

Price Change

Last Dividend USD

B+

Latest Rating

OGN's stock peer is AZN (AstraZeneca PLC)

OGN's stock peer is BMY (Bristol-Myers Squibb Company)

OGN's stock peer is GILD (Gilead Sciences, Inc.)

OGN's stock peer is JNJ (Johnson & Johnson)

OGN's stock peer is LLY (Eli Lilly and Company)

OGN's stock peer is MRK (Merck & Co., Inc.)

Healthcare Drug Manufacturers - General

Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology products, including Ontruzant and Aybintio. It also offers cardiovascular products, consisting of several cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for various treatments to control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. In addition, the company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products primarily to drug wholesalers and retailers, hospitals, and government agencies, as well as managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was incorporated in 2020 and is based in Jersey City, New Jersey.

100%

Dcf Rating

100%

Return On Equity

100%

Return On Assets

20%

Debt To Equity

40%

Price To Earnings

20%

Price To Book

Income Statement

Dividend Stats Yield is calculated via trailing-12-month period

Ex-Dividend	Payment Date	Dividend	Yield	Dividend Frequency
2025-05-12	2025-06-12	0.02	9.87 %	Quarterly
2025-02-24	2025-03-13	0.28	7.43 %	Quarterly
2024-11-12	2024-12-12	0.28	7.19 %	Quarterly
2024-08-16	2024-09-12	0.28	5.50 %	Quarterly
2024-05-13	2024-06-13	0.28	5.48 %	Quarterly
2024-02-26	2024-03-14	0.28	6.05 %	Quarterly
2023-11-13	2023-12-14	0.28	10.07 %	Quarterly
2023-08-18	2023-09-14	0.28	4.99 %	Quarterly
2023-05-15	2023-06-15	0.28	5.37 %	Quarterly
2023-02-27	2023-03-16	0.28	4.38 %	Quarterly
2022-11-14	2022-12-15	0.28	4.53 %	Quarterly
2022-08-15	2022-09-15	0.28	3.61 %	Quarterly
2022-05-16	2022-06-16	0.28	2.40 %	Quarterly
2022-02-28	2022-03-17	0.28	1.49 %	Quarterly
2021-11-22	2021-12-16	0.28	0.90 %	Quarterly
2021-08-23	2021-09-13	0.28	0.84 %	Quarterly

Recent News

Organon & Co. (OGN) Lawsuit - Investors Urged to Contact Levi & Korsinsky Before July 22, 2025

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151604&wire=1&utm_campaign=4 or contact Joseph E. Levi, Esq.

2025-06-04 09:30:00

OGN LAWSUIT NOTICE: Lose Money on Organon & Co.? BFA Law Alerts Investors that the Class Action Could Allow Investors to Recover Losses (NYSE:OGN)

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against Organon & Co. (NYSE: OGN) and certain of the Company's senior executives for potential violations of the federal securities laws. If you invested in Organon you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/organon-co-class-action.

2025-06-04 09:17:00

Shareholders of Organon & Co. (OGN): Protect Your Rights Before July 22, 2025 - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151559&wire=1&utm_campaign=21 or contact Joseph E. Levi, Esq.

2025-06-04 07:20:00

OGN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Organon & Co. Investors Have Opportunity to Lead Class Action Lawsuit!

NEW YORK CITY, NY / ACCESS Newswire / June 4, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Organon & Co. ("Organon" or "the Company") (NYSE:OGN) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Organon securities between October 31, 2024 and April 30, 2025, both dates inclusive (the "Class Period").

2025-06-04 07:00:00

Class Action Lawsuit Alert: Levi & Korsinsky Reminds Organon & Co. (OGN) Investors of July 22, 2025 Deadline

NEW YORK, NY / ACCESS Newswire / June 4, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151532&wire=1&utm_campaign=16 or contact Joseph E. Levi, Esq.

2025-06-04 05:45:00

Did You Lose Money on Organon & Co. (OGN)? Levi & Korsinsky Urges Investors to Act Before July 22, 2025

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151527&wire=1&utm_campaign=28 or contact Joseph E. Levi, Esq.

2025-06-03 23:00:00

ORGANON SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Organon & Co. - OGN

NEW YORK and NEW ORLEANS, June 03, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until July 22, 2025 to file lead plaintiff applications in a securities class action lawsuit against Organon & Co. (NYSE: OGN), if they purchased the Company's securities between October 31, 2024 and April 30, 2025, inclusive (the “Class Period”). This action is pending in the United States District Court for the District of New Jersey.

2025-06-03 22:32:00

Class Action Filed Against Organon & Co. (OGN) Over Securities Violations - Contact Levi & Korsinsky Today

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151519&wire=1&utm_campaign=29 or contact Joseph E. Levi, Esq.

2025-06-03 17:30:00

OGN Stock Alert: Organon & Co. Shareholders with Large Losses Should Contact Robbins LLP for Information on Leading the Class Action Lawsuit

SAN DIEGO, June 03, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of investors who purchased or otherwise acquired Organon & Co. (NYSE: OGN) securities between October 31, 2024 and April 30, 2025. Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives.

2025-06-03 17:11:00

Lost Money on Organon & Co. (OGN)? Urged to Join Class Action Before July 22, 2025 - Contact Levi & Korsinsky

NEW YORK, NY / ACCESS Newswire / June 3, 2025 / If you suffered a loss on your Organon & Co. (NYSE:OGN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/organon-co-lawsuit-submission-form?prid=151500&wire=1&utm_campaign=22 or contact Joseph E. Levi, Esq.

2025-06-03 16:00:00

Disclaimers

StockQuay.com is not operated by a broker, dealer, or registered investment advisor. Under no circumstances should any information published on StockQuay.com be considered a recommendation to buy, sell, or hold any security. The content on this site and in its associated newsletters is intended solely for informational and educational purposes and does not constitute investment advice or financial recommendations.

Individuals or entities featured or referenced on StockQuay.com may engage in trading activity involving the securities mentioned in any article or report before or after such content is published. These individuals or entities are not affiliated with StockQuay.com, and their inclusion does not imply endorsement or accuracy of their views or actions.

StockQuay.com, its owners, or its affiliates shall not be held liable to any user or third party for any damages or losses arising from the use of content on this website. This includes, but is not limited to, investment losses, loss of profit, loss of data, missed opportunities, or indirect, incidental, or consequential damages.

Data is updated daily and is not guaranteed to be accurate or complete.

Past performance is not indicative of future results. Please conduct your own research or consult with a qualified financial advisor before making any investment decisions